Codexis Inc (CDXS) Stock Price, Quote & News

Company Profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 421 8100

Website: www.codexis.com

Address:

200 Penobscot Drive, Redwood City, United States

djohndjohn Jun. 22 at 9:19 PM

$CDXS Stephen G. DillyDally😀, M.B.B.S., Ph.D. received 47,074,970 votes in favor,😁 6,891,598 votes withheld😁, and 20,771,912 broker non-votes. 6,891,598 votes withheld, That's about the same amount of shares that Opaleye(AKA Jimmy)owns. Jimmy don't like DillyDally. I'm begining to feel the same way

0 · Reply

galaxySky Jun. 22 at 8:50 PM

$CDXS surprised this is disconnected from xbi. Macro trends aren't affecting it, sus..

0 · Reply

djohndjohn Jun. 22 at 4:42 PM

$CDXS Dilly and BoD are a bunch of Bozo's Gave themselves way too many options with an exercise price of $2.48. Basically saying the stock is worth $2.48. Better get off their duff's and add some value for the shareholders

0 · Reply

Fingerlickengood Jun. 19 at 3:13 PM

I believe the writing is on the wall, $MRK completely owning $CDXS IP now makes complete sense!

2 · Reply

Fingerlickengood Jun. 19 at 1:03 PM

$CDXS $MRK "Protillion’s Prot-MaP™ technology and Codexis’ ECO Synthesis® platform represent two complementary frontiers in biotherapeutic engineering: Prot-MaP focuses on ultra-high-throughput, AI-driven protein discovery and optimization, while ECO Synthesis focuses on scalable, green therapeutic RNA manufacturing. Together, they showcase the industry-wide shift toward integrating automated high-throughput biology, AI, and green biocatalysis to overcome traditional drug development bottlenecks. While Protillion’s primary focus is on protein/antibody design (amino acids) and Codexis' ECO platform is generally for RNA/oligonucleotides, the two technologies could intersect if a developer is working on complex conjugate therapies or if Codexis applies its enzyme technology to peptide/protein manufacturing."

4 · Reply

JulesRocketManVern Jun. 18 at 6:56 PM

$CDXS hit the break out..... Come on!

0 · Reply

Trq2507 Jun. 18 at 5:44 PM

$CDXS takeover @ $9.50

0 · Reply

Kanate123 Jun. 18 at 1:28 PM

$RUM $CDXS bet the ranch a trie lottery ticket

1 · Reply

Kanate123 Jun. 18 at 1:24 PM

$QS also buy Codexis $CDXS a triple from here check out cantor fitzgerald 11 price yesterday

2 · Reply

Kanate123 Jun. 18 at 1:20 PM

$QS this is another good runner, but I also own a ton of codexis . I took a major position in yesterday Canter raised and reiterates an $11 stock price. This is at least a triple if not more. $CDXS I bet the ranch big-time

0 · Reply

Codexis Transcript: AGM 2026

Jun 2, 2026, 7:00 AM EDT - 21 days ago

Codexis Slides: Corporate presentation

2026-05-07T22:52:18.000Z - 6 weeks ago

Codexis reports Q1 EPS (10c), consensus (10c)

2026-05-07T22:51:14.000Z - 6 weeks ago

Codexis backs FY26 revenue view $72M-$76M, consensus $74.24M

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Codexis Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Codexis Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Codexis Quarterly report: Q1 2026

May 7, 2026, 4:05 PM EDT - 6 weeks ago

Codexis Reports First Quarter 2026 Financial Results

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

Codexis to share RNA manufacturing advances at TIDES USA

Apr 28, 2026, 8:00 AM EDT - 7 weeks ago

Codexis Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 7 weeks ago

Codexis Proxy statement: Proxy filing

Mar 11, 2026, 4:30 PM EDT - 3 months ago

Codexis Earnings Call Transcript: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 3 months ago

Codexis Annual report: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 3 months ago

Codexis Earnings release: Q4 2025

2026-03-11T20:25:25.000Z - 3 months ago

Codexis reports Q4 EPS 11c, consensus (4c)

2026-03-11T20:25:07.000Z - 3 months ago

Codexis sees FY26 revenue $72M-$76M, consensus $70.8M

Mar 11, 2026, 4:05 PM EDT - 3 months ago

Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

2026-03-04T15:11:46.000Z - 3 months ago

Codexis announces agreement to manufacture 50 g siRNA

Mar 4, 2026, 10:06 AM EST - 3 months ago

Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform

Mar 3, 2026, 11:50 AM EST - 3 months ago

Codexis Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 9:00 AM EST - 4 months ago

Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11

2026-02-10T14:05:57.000Z - 4 months ago

Codexis achieves ISO 9001:2015 certification

Feb 10, 2026, 9:00 AM EST - 4 months ago

Codexis Achieves ISO 9001:2015 Certification

2026-01-07T14:12:08.000Z - 5 months ago

Codexis signs evaluation agreement with Axolabs

Jan 7, 2026, 9:00 AM EST - 5 months ago

Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics

2025-11-10T14:11:19.000Z - 8 months ago

Codexis announces signing of lease for GMP manufacturing facility

Nov 10, 2025, 9:00 AM EST - 8 months ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility

2025-11-06T22:35:34.000Z - 8 months ago

Codexis reports Q3 EPS (22c), consensus (13c)

Nov 6, 2025, 4:30 PM EST - 8 months ago

Codexis Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Codexis Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Codexis Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 8 months ago

Codexis Slides: Q3 2025

2025-10-29T14:05:32.000Z - 8 months ago

Codexis, Nitto Denko Avecia enter evaluation agreement

Oct 29, 2025, 9:58 AM EDT - 8 months ago

Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing

Oct 23, 2025, 7:05 AM EDT - 8 months ago

Codexis to Report Third Quarter 2025 Financial Results on November 6

Sep 4, 2025, 3:55 PM EDT - 10 months ago

Codexis Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 9:00 AM EDT - 10 months ago

Codexis to Participate in Cantor Global Healthcare Conference

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Codexis Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Codexis Quarterly report: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Codexis Earnings release: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 11 months ago

Codexis Slides: Q2 2025

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Codexis Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 11 months ago

Codexis to Report Second Quarter 2025 Financial Results on August 13

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Codexis Transcript: Jefferies Global Healthcare Conference 2025

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Transcript: Status Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Press release: Status Update

2025-05-22T11:10:44.000Z - 1 year ago

Codexis presents data on ECO Synthesis platform at TIDES USA meeting

May 22, 2025, 7:00 AM EDT - 1 year ago

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

May 21, 2025, 4:05 PM EDT - 1 year ago

Codexis to Participate in Jefferies Global Healthcare Conference

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Slides: Q1 2025

2025-05-14T20:16:47.000Z - 1 year ago

Codexis reports Q1 EPS (25c), consensus (21c)

2025-05-14T20:16:39.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $65.67M

May 14, 2025, 4:05 PM EDT - 1 year ago

Codexis Reports First Quarter 2025 Financial Results

May 7, 2025, 7:00 AM EDT - 1 year ago

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Codexis to Report First Quarter 2025 Financial Results on May 14

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Codexis Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Codexis Proxy statement: Proxy Filing

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Codexis Announces Byron Dorgan to Retire from Board of Directors

2025-04-01T11:21:28.000Z - 1 year ago

Codexis appoints Cynthia Collins to board of directors

2025-03-25T19:37:37.000Z - 1 year ago

Investors should buy Codexis following contract news, says Craig-Hallum

ALNY DHR

2025-03-24T11:20:13.000Z - 1 year ago

Codexis announces first revenue-generating contract for ECO Synthesis services

Mar 7, 2025, 4:05 PM EST - 1 year ago

Codexis Announces New Employment Inducement Grants

Mar 4, 2025, 1:10 PM EST - 1 year ago

Codexis Transcript: TD Cowen 45th Annual Healthcare Conference

2025-02-27T22:00:31.000Z - 1 year ago

Codexis reports Q4 EPS (13c), consensus (2c)

2025-02-27T22:00:23.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $66.61M

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Slides: Q4 2024

Feb 13, 2025, 4:05 PM EST - 1 year ago

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Feb 6, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors

Dec 3, 2024, 11:00 AM EST - 1 year ago

Codexis Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 1:00 PM EST - 1 year ago

Codexis Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 19, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:30 AM EST - 1 year ago

Codexis Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 2:25 PM EST - 1 year ago

Codexis Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Transcript: Status Update

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Press release: Status Update

Nov 14, 2024, 4:05 PM EST - 1 year ago

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

Nov 12, 2024, 4:05 PM EST - 1 year ago

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

Nov 11, 2024, 4:05 PM EST - 1 year ago

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Slides: Q3 2024

Oct 24, 2024, 4:05 PM EDT - 1 year ago

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Codexis to Report Third Quarter 2024 Financial Results on October 31

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Oct 1, 2024, 7:05 AM EDT - 1 year ago

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Sep 17, 2024, 11:30 AM EDT - 1 year ago

Codexis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 20, 2024, 4:05 PM EDT - 1 year ago

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Aug 15, 2024, 4:05 PM EDT - 2 years ago

Codexis Publishes FY2023 Sustainability Disclosures

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Slides: Q2 2024

Jul 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report Second Quarter 2024 Financial Results on August 8

Jul 1, 2024, 4:05 PM EDT - 2 years ago

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Codexis Transcript: Jefferies Global Healthcare Conference

May 20, 2024, 4:05 PM EDT - 2 years ago

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

May 14, 2024, 6:00 AM EDT - 2 years ago

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings release: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Slides: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Codexis Registration statement: Registration Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Codexis Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Codexis Proxy statement: Proxy Filing

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 11, 2024, 7:05 AM EDT - 2 years ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Mar 4, 2024, 2:50 PM EST - 2 years ago

Codexis Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Annual report: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings release: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Slides: Q4 2023

Feb 28, 2024, 4:05 PM EST - 2 years ago

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

Feb 26, 2024, 8:05 AM EST - 2 years ago

Codexis to Participate in TD Cowen 44th Annual Health Care Conference

Feb 20, 2024, 8:05 AM EST - 2 years ago

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Feb 14, 2024, 4:05 PM EST - 2 years ago

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28

Feb 13, 2024, 4:05 PM EST - 2 years ago

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones

Feb 1, 2024, 4:05 PM EST - 2 years ago

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Dec 27, 2023, 8:30 AM EST - 2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Dec 13, 2023, 4:06 PM EST - 2 years ago

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Dec 13, 2023, 4:05 PM EST - 2 years ago

Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform

djohndjohn Jun. 22 at 9:19 PM

0 · Reply

galaxySky Jun. 22 at 8:50 PM

$CDXS surprised this is disconnected from xbi. Macro trends aren't affecting it, sus..

0 · Reply

djohndjohn Jun. 22 at 4:42 PM

0 · Reply

Fingerlickengood Jun. 19 at 3:13 PM

I believe the writing is on the wall, $MRK completely owning $CDXS IP now makes complete sense!

2 · Reply

Fingerlickengood Jun. 19 at 1:03 PM

4 · Reply

JulesRocketManVern Jun. 18 at 6:56 PM

$CDXS hit the break out..... Come on!

0 · Reply

Trq2507 Jun. 18 at 5:44 PM

$CDXS takeover @ $9.50

0 · Reply

Kanate123 Jun. 18 at 1:28 PM

$RUM $CDXS bet the ranch a trie lottery ticket

1 · Reply

Kanate123 Jun. 18 at 1:24 PM

$QS also buy Codexis $CDXS a triple from here check out cantor fitzgerald 11 price yesterday

2 · Reply

Kanate123 Jun. 18 at 1:20 PM

0 · Reply

Kanate123 Jun. 18 at 1:16 PM

$RUM definitely number one Stock also buy $CDXS this company is a lottery ticket with Canter Fitzgerald, putting $11 price target on it. This is a no-brainer also for a takeover.

0 · Reply

Kanate123 Jun. 18 at 1:07 PM

$VCX $CDXS - this is a triple stock here easily look what cooper said about it yesterday or a buyout easily take over target

0 · Reply

Kanate123 Jun. 18 at 1:04 PM

$RUMBW you also must own $CDXS this is a lottery ticket where the stock will at least triple per Share look at Canter reiterating an $11 price target yesterday. This is a no-brainer. You’ve gotta buy it.

0 · Reply

Kanate123 Jun. 18 at 1:03 PM

$CAST $CDXS -both of these stocks are must owned this is a lottery ticket and then no-brainer at least the triple on the stock.look at cantor fitzgeerald they reiterated the price to $11

0 · Reply

Kanate123 Jun. 18 at 1:00 PM

$JBL you must also own codexis $CDXS - a buyout

0 · Reply

Kanate123 Jun. 18 at 12:59 PM

$RUM $CDXS - I love rum Stock, but I also like codexis . $CDXS this is a lottery ticket and at least a triple look at Canter’s recommendation yesterday. $11.

0 · Reply

Kanate123 Jun. 18 at 12:54 PM

$RUM $CDXS if you dont buy codexis you’re a fool. this company is at least a triple canter put a $11 price target on it yesterday. Buy this lottery ticket today and leave it alone.

0 · Reply

Kanate123 Jun. 18 at 12:48 PM

$RUM I love rum, but you have to own codexis also .$CDXS

0 · Reply

Kanate123 Jun. 18 at 12:39 PM

$LPA - $CDXS this company codexis os a lottery ticket buy. a 11 price by cantor yesteesa a teiple at least takeover

0 · Reply

Kanate123 Jun. 18 at 12:37 PM

$CAST - $CDXS this stock is a lottery ticket buy it . cantor put a 11 price target . takeover

0 · Reply

Kanate123 Jun. 18 at 12:32 PM

$CAST $CDXS a lottery ticket a must buy

0 · Reply

Kanate123 Jun. 18 at 12:29 PM

$CAST - $CDXS - this company is a must own a triple at least cantor fitz just just said yesterday 11.00 u must own this lottery ticket

0 · Reply

Market Cap	233.61M
Revenue (ttm)	70.39M
Net Income (ttm)	-43.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-62.47%
Debt to Equity Ratio	0.94

Volume	1,050,900
Avg Vol	1,047,802
Day's Range	N/A - N/A
Shares Out	90.90M
Stochastic %K	11%
Beta	2.48
Analysts	Strong Sell
Price Target	$6.58